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The angiogenic activity of peptide adrenomedullin (AM) was first shown in 1998 . Since then, a number of reports have confirmed the
ability of AM to induce the growth and migration of isolated vascular endothelial and smooth muscle cells in vitro and to promote
angiogenesis in xenografted tumours in vivo. In addition, knockout murine models point to an essential role for AM in embryonic
vasculogenesis and ischaemic revascularisation. AM expression is upregulated by hypoxia (a typical feature of solid tumours) and a
potential role as a regulator of carcinogenesis and tumour progression has been proposed based on studies in vitro and in animal
models. Nevertheless, translational research on AM, and in particular, confirmation of its importance in the vascularisation of human
tumours has lagged behind. In this commentary, we review current progress and potential directions for future research into the role
of AM in tumour angiogenesis.
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The increased risk of endometrial polyps, hyperplasia and cancer
in women receiving tamoxifen treatment for breast cancer
prompted our group to look for genes induced in endometrial
isolates by tamoxifen, but not oestrogen. PCR differential display
identified the vasoactive peptide adrenomedullin (AM) as
one such gene (Zhao et al, 1998). We subsequently showed AM
to be an endothelial cell growth factor, having potent in vivo
angiogenic activity and promoting tumour growth in animal
models (Zhao et al, 1998; Nikitenko et al, 2000; Oehler et al, 2001,
2002). The last 7 years have seen increasing interest in elucidating
a role of AM in tumorigenesis. The purpose of this commentary is
to review those studies and to identify current unanswered
questions.
ADRENOMEDULLIN
Adrenomedullin peptide
Andrenomedullin is a 52-amino-acid peptide originally isolated
from a human phaeochromocytoma (Kitamura et al, 1993a). It is
produced through cleavage of a 185-amino-acid prohormone
(pre-proadrenomedullin), which also yields proadrenomedullin
N-terminal 20 peptide (PAMP). Andrenomedullin belongs to the
calcitonin gene peptide superfamily based on its homology with
calcitonin gene-related peptide (CGRP) and amylin (Poyner et al,
2002). The pleiotropic activities of AM were recognised within a
few years of its initial characterisation as a vasodilatory peptide
(Kitamura et al, 1993a; reviewed by Hinson et al, 2000). The
expression and secretion of AM has been demonstrated in many
tumours and biological fluids and it has been implicated in the
modulation of numerous physiological processes (reviewed in
Hinson et al, 2000). For example: (1) it is a growth factor (Hinson
et al, 2000), (2) it is angiogenic in in vitro models and in vivo,
(Zhao et al, 1998; Nikitenko et al, 2000; Kim et al, 2003), (3) it
inhibits apoptosis in endothelium and isolated tumour cells (Kato
et al, 1997; Martinez et al, 2002; Oehler et al, 2002), (4) it is a
potent vasodilator (reviewed by Hinson et al, 2000), (5) it regulates
endothelial permeability (Hippenstiel et al, 2002), and (6) it
contributes to adhesion and differentiation of bone marrow-
derived mononuclear cells into endothelial progenitor cells (Iwase
et al, 2005).
Regulation of adrenomedullin expression
Andrenomedullin expression is stimulated by cytokines and
hypoxia and its promoter contains several putative hypoxia
response elements (reviewed by Zudaire et al, 2003). Hypoxia
induces AM expression and secretion in many cell types including
carcinoma cell lines (endometrial, breast, neuroblastoma, colo-
rectal) (reviewed by Zudaire et al, 2003) and endothelial cells
(Nakayama et al, 1999; Nikitenko et al, 2003). Hypoxia is a
frequent feature of the microenvironment in solid tumours and
constitutes one of the driving forces of cancer growth and
progression (Harris, 2002), and a role for AM as a promoter of
these processes has been suggested (Oehler et al, 2001; Martinez
et al, 2002; Ouafik et al, 2002).
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adrenomedullin binding protein
A specific AM binding protein (i.e., AMBP-1) has been described
and characterised as human complement factor H (reviewed by
Zudaire et al, 2003). Binding proteins can limit the transport of a
peptide to the interstitial space and access to its specific receptors,
modulate its biological activity, as well as protecting it from
metabolic clearance by proteases and thereby prolonging the
half-life in the circulation. This could explain why the growth
promoting activity of AM is augmented in the presence of AMBP-1
(reviewed by Zudaire et al, 2003).
Adrenomedullin receptors
AM mediates its activities via heterodimeric receptors that are
composed of a seven transmembrane (7TM) G-protein-coupled
receptor (GPCR) calcitonin-receptor-like receptor (CRLR, now
known as CL; Poyner et al, 2002), and a receptor activity modifying
protein (RAMP) (McLatchie et al, 1998). The RAMP family
comprises three members (RAMP1, RAMP2 and RAMP3) that
share less than 30% sequence identity but a common topological
organisation. They are small intrinsic membrane proteins with a
large extracellular N-terminus (B100 amino acids), a single
transmembrane domain, and a short intracellular domain (10
amino acids). Formation of heterodimers between RAMPs and CL
is essential for proper cell surface targeting and to define ligand-
binding selectivity of this GPCR (McLatchie et al, 1998). RAMP2
and RAMP3 promote the expression of AM receptors (termed
AM1 and AM2, respectively), while coexpression of RAMP1
with CL leads to the formation of CGRP receptor (McLatchie
et al, 1998; Poyner et al, 2002) (Figure 1). However, the
mechanisms regulating CL and RAMPs expression remain poorly
characterised.
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Figure 1 Role of adrenomedullin in tumour progression. The role of hypoxia and inflammatory cytokines in regulation of AM expression and secretion by
tumour cells in vivo has been suggested. Adrenomedullin promotes formation of xenografted tumours by stimulation of autocrine growth and survival of
tumour cells, and through paracrine effects on surrounding vessels. Possible intracellular signalling mechanisms underlying effects of AM in tumour
microenvironment (in endothelial, vascular smooth muscle (VSMC) and tumour cells) suggest its potential role in tumorigenesis, resistance to chemotherapy
and tumour progression. Based on McLatchie et al (1998), Shichiri et al (1999), Hinson et al (2000), Oehler et al (2001), Martinez et al (2002), Poyner et al
(2002), Kim et al (2003) and Iwase et al (2005). AC¼adenylate cyclase; GC¼guanylate cyclase; PKA¼protein kinase A, PKG¼protein kinase G,
PLC¼phospholipase C, MEK¼mitogen-activated protein kinase kinase; ERK¼extracellular signal-regulated kinase (also termed MAPK).
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Adrenomedullin signal transduction differs between cell types,
involving several pathways (Figure 1). Increasing evidence has
shown that activation or disruption of AM signalling may
contribute to pathologies including ischaemia-induced damage
and neoplastic growth (reviewed in Hinson et al, 2000; reviewed in
Nikitenko et al, 2002). It follows that the development of drugs
modulating AM activity hold the potential for pro- or antiangio-
genic therapies.
ADRENOMEDULLIN AND CANCER
Adrenomedullin has been shown to be involved in carcinogenesis
and tumour progression by promoting tumour proliferation,
angiogenesis and the inhibition of apoptosis. It is thought that
inflammatory cytokines- and hypoxia–induced expression of AM
by tumour cells drives these processes (Figure 1).
Adrenomedullin and tumour cell proliferation
Several AM-overexpressing human carcinoma cell lines exhibit
enhanced growth in vitro and in vivo to a varying degree (Oehler
et al, 2001; Martinez et al, 2002). Thus, the endometrial cancer cell
line RL95.2 overexpressing AM showed a marked growth increase,
but no increase was seen with Ishikawa-transfected endometrial
carcinoma cells (Oehler et al, 2001). Adrenomedullin also
maintains cell proliferation of breast tumour cell lines T47D in
serum-free conditions (Martinez et al, 2002). Finally, an anti-AM
antibody significantly decreased in vitro and in vivo growth of U87
glioblastoma cells that have a high level of endogenous AM (Ouafik
et al, 2002).
Adrenomedullin and angiogenesis
A role for AM in physiological and pathological angiogenesis has
been demonstrated using several in vitro, knockout mice and
xenografted tumour models (Zhao et al, 1998; Hague et al, 2000;
Nikitenko et al, 2000; Oehler et al, 2001; Fujita et al, 2002; Martinez
et al, 2002; Kim et al, 2003) (Figure 2).
AM plays a role in the regulation of angiogenesis in the female
reproductive tract (Nikitenko et al, 2000), during embryonic
vascular development (Caron and Smithies, 2001; Shindo et al,
2001), and during vascular remodelling in response to ischaemia
(Iimuro et al, 2004; Matsui et al, 2004). Thus, AM induces growth
of human endometrial microvascular endothelial cells (Nikitenko
et al, 2000). Studies using AM knockout mice suggest that AM is
essential for vascular morphogenesis (Caron and Smithies, 2001;
Shindo et al, 2001). Adrenomedullin also augments blood flow
recovery and collateral capillary development in response to acute
ischaemia (Abe et al, 2003).
Similarly, AM is considered to be angiogenic in tumours. For
example, in leiomyomas, benign myometrial tumours, AM
expression correlates with vascular density and the endothelial
cell proliferation index (Hague et al, 2000). In xenografted tumour
models utilising human endometrial, breast or pancreatic tumour
cell lines, vascular density or directed growth of blood vessels was
increased in AM-overexpressing transfectants (Oehler et al, 2001;
Martinez et al, 2002; Ishikawa et al, 2003). Similar effects were
observed after xenografting human glioblastoma cells, that were
known to express high levels of endogenous AM (Ouafik et al,
2002). These observations have been confirmed in AM-hetero-
zygous knockout mice, where decreased xenografted tumour
growth and reduced neovascularisation in ischaemic conditions
were observed (Iimuro et al, 2004).
A role for AM in vascular maturation has also been suggested
(Iwase et al, 2005). AM stimulation of vascular smooth muscle cell
(VSMC) migration and endothelium-independent vasodilatation
may contribute to vascular maturation. Recent studies show that
AM not only enhances the differentiation of bone marrow-derived
mononuclear cells into endothelial cells but also facilitates
formation of mature vessels that include VSMC (Iwase et al,
2005). In contrast, others demonstrated that endogenous AM could
protect against pulmonary vascular remodelling induced by
hypoxia or limit the arterial intimal hyperplasia induced by injury
(Kawai et al, 2004; Matsui et al, 2004).
Finally, a role for PAMP in angiogenesis has also been suggested
(Martinez et al, 2004b).
Adrenomedullin and apoptosis
Adrenomedullin inhibits apoptosis of both endothelial and tumour
cells. For example, AM suppresses serum deprivation-induced
apoptosis in rat endothelial cells (Kato et al, 1997). Stably
transfected AM-overexpressing endometrial tumour cells show
resistance to hypoxia-induced apoptosis via a bcl-2-mediated
mechanism (Oehler et al, 2002). Furthermore, AM-overexpressing
breast carcinoma cells show lower levels of proapoptotic factors
such as Bax, Bid and caspase 8, concomitant with higher resistance
to apoptosis (after serum deprivation), than cells transfected with
the empty vector (Martinez et al, 2002).
ADRENOMEDULLIN RECEPTORS AND SIGNALLING
IN TUMOUR BIOLOGY
Currently CL is considered to be the main receptor mediating AM
effects (McLatchie et al, 1998; Poyner et al, 2002). In normal tissues
CL is predominantly expressed in microvascular endothelial cells,
supporting the view that this GPCR is potentially a major regulator
of the effects of AM on vasculature (Nikitenko et al, 2003).
Calcitonin-receptor-like receptor gene transcription is upregulated
in endothelial cells in hypoxia. Simultaneous transcriptional
upregulation of CL and it ligand AM in endothelial cells might
play a significant role in vascular responses to hypoxia and
ischaemia by creating a survival loop. Calcitonin-receptor-like
receptor is also upregulated in some human tumours (Nikitenko
et al, 2003).
In vascular endothelial cells, activation of phosphatydylinositol
30kinase (PI3K/Akt), mitogen-activated protein kinase (MAPK)
and focal adhesion kinase (p125FAK) plays a role in AM-induced
angiogenesis (Figure 1). Thus, AM-stimulated migration of human
umbilical vein endothelial cells (HUVEC) is inhibited by PI3K- or
MAPK-inhibitors (Kim et al, 2003). Nitric oxide (NO) upregulation
by AM has been implicated in endothelium-dependent vasodilata-
tion (reviewed in Hinson et al, 2000). Adrenomedullin reduces
endothelial apoptosis via a c-AMP-independent mechanism, and
by upregulation of transcription factor Max (Kato et al, 1997;
Shichiri et al, 1999).
The mitogenic activity of AM on VSMC is mediated via a cAMP-
dependent pathway and/or a MAPK (reviewed by Hinson et al,
2000). Endothelium-independent vasodilatory effects of AM are
mediated via a cAMP-dependent mechanism in VSMC (Figure 1).
Adrenomedullin-stimulated VSMC migration is inhibited by
wortmannin, a PI3K inhibitor, and it has been suggested that
activation of PI3K/Akt by the peptide in vivo contributes to
recruitment of VSMC to a newly formed capillary network (Iwase
et al, 2005). Stimulation of vascular maturation by a direct effect
of AM on VSMC is in sharp contrast to VEGF that stimulates new
vessel formation but not maturation. Whether AM and VEGF act
synergistically or independently remains to be elucidated. Two
recent studies have shown that AM enhances vascular endothelial
growth factor (VEGF)-induced capillary formation by HUVEC in
vitro, but there is disagreement on the ability of AM to stimulate
VEGF production in these cells (Fernandez-Sauze et al, 2004;
Iimuro et al, 2004).
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of oncogenic proteins such as Ras, Raf, PKC and MAPKp49 and
incorporate more bromodeoxiuridine (after serum deprivation)
compared to controls (Martinez et al, 2002) (Figure 1). Adreno-
medullin-mediated upregulation of antiapoptotic factors in
hypoxia or downregulation of pro-apoptotic factors contributes
to tumour cell survival (Oehler et al, 2001; Martinez et al, 2002).
Further, AMBP-1 enhances AM-mediated growth in breast cancer
cell lines and has been recently implicated in a mechanism leading
to tumour cell survival by resistance to complement-mediated lysis
(reviewed in Zudaire et al, 2003). However, the role of AMBP-1 in
protection of tumour cells from apoptosis is unknown and further
studies are needed.
ADRENOMEDULLIN AND TUMOUR THERAPY
Several strategies have been proposed to inhibit AM-induced
angiogenesis and tumour cell growth and survival. Among these are
approaches that aim to: (1) modulate AM expression (AM mRNA
rybozyme), (2) alter AM binding to its receptor (anti-AM blocking
antibodies, receptor antagonists, truncated peptides, e.g., AM22–52 and
CGRP8–37, and small nonpeptide molecules), or (3) inhibit specific
AM-induced intracellular signalling pathways (e.g. using anti-CL or
anti-RAMPs blocking antibodies, inhibitors of PI3K/Akt or MAPK
pathways and other angiostatic molecules, e.g., vinblastine) (Table 1).
Several such strategies have successfully attenuated AM-induced
signalling and inhibited endothelial cell growth and migration, or
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Figure 2 Angiogenic effects of adrenomedullin in vitro and in vivo. Adrenomedullin promotes (A) growth of new blood vessels in vivo in chicken
chorioallantoic membrane assay (CAM), (B) proliferation of human endometrial microvascular endothelial cells and (C) migration of human dermal
microvascular endothelial cells in vitro. CAM and proliferation assays were performed as described (from Zhao et al, 1998; Nikitenko et al, 2000). For
migration assay, cells were seeded into the upper chamber of the transwell apparatus, and AM added into the lower chamber. The number of cells that
migrated to the lower surface was dose-dependent (AM 10
–10–10
–6M) compared to the control. (D) Adrenomedullin promotes formation of xenografted
endometrial tumours. The suggested mechanisms include stimulation of autocrine growth and angiogenesis in AM-overexpressing RL95.2 tumours (Clones
RL-ADM1 and RL-ADM2) (from Oehler et al, 2002). (A and D) are reproduced by kind permission of Oncogene (Nature Publishing Group) from Zhao et al
(1998) and Oehler et al (2002). Each point represents the mean7s.e.m. (*Po0.05; **Po0.01; ***Po0.001; as compared to controls).
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demonstrated that loss of AM results in elevated blood pressure
(Shindo et al, 2001), which could be a problem in blocking therapies.
CLINICAL RELEVANCE OF ADRENOMEDULLIN AND ITS
RECEPTORS IN CANCER AND FUTURE
TRANSLATIONAL RESEARCH
Although the role of AM has been studied using in vitro and
murine xenografted tumour models, studies in man have been
limited to use of cancer cell lines and a few tumours.
Currently, immunohistochemistry and RT–PCR have been the first
choice with which to study AM expression and distribution in human
tumour tissues, but there is a paucity of quantitative data. There
is also little data concerning which cells express the messenger RNA
within tumours (Rocchi et al, 2001). A few studies have been
performed to measure peptide levels in blood or tumour tissues from
sufficient number of patients to enable statistical analysis (Satoh et al,
1995; Oehler et al, 2003). For example, it has been shown that the
plasma AM level in breast cancer patients correlates with primary
tumour size and lymph node metastasis (P¼0.002), as measured by
radioimmunoassay (Oehler et al, 2003). However, despite the fact
that plasma AM may be an independent predictor of lymph node
metastasis, it was concluded that it is unlikely to be a useful tumour
marker for the detection of breast cancer.
The correlation of AM mRNA expression with tumour stage has
been demonstrated only for human glioblastomas (Ouafik et al,
2002). Its correlation with vascular density has been demonstrated
in renal tumours and uterine leiomyoma (Hague et al, 2000; Fujita
et al, 2002). However, the small patient number used in the first
two studies (with a maximum of six and 12 samples per group,
respectively) limits reliable conclusions. Studies by Hague et al
(2000) did not examine correlations within leiomyoma-bearing
uteri, making it difficult to assess the potential of anti-AM
strategies and their possible effects on surrounding myometrium.
Finally, no studies have yet used quantitative methods to assess
the mRNA and protein expression levels for components of the
AM receptor system (CL and RAMPs). Information on the
distribution, regulation and function of endogenous AM receptors
is poor, and data on their role in human tumour biology is not
available. CL mRNA might be upregulated in some tumour types
(Nikitenko et al, 2003), but little information is available on
protein expression, receptor distribution, or concerning CL-
mediated signalling pathways involved in human tumours. RAMPs
2 and 3 mRNAs have also been found in some tumour types, but
no studies have characterised the expression of functional
endogenous AM receptors and their role in tumorigenesis. Thus
there is still much to be learned about their role in human cancer
especially in regards to translational research (Liang, 2003).
CONCLUDING REMARKS, UNANSWERED QUESTIONS
AND FUTURE DIRECTIONS
Validation of adrenomedullin as a tumour expressed gene
Several studies have shown that expression of AM by tumour models
enhances tumour growth and angiogenesis, whereas blocking AM
antibodies have the reverse effect. While these observations point to
Table 1 Specific and nonspecific modulators of adrenomedullin-induced effects
Target Drug
Mode of action/
biological activity
Side-effects/
disadvantages
Antiangiogenic
potential Reference
Specific modulators of AM-induced effects
Ligand (adrenomedullin) AM mRNA rybozyme AM mRNA degradation Lack of reliable targeted
delivery
Not tested Taylor and Samson
(2002)
AMBP-1 (binding protein) Affinity to receptor is
unaltered
Protection of peptide from
degradation by proteases
Not tested Not tested Reviewed by Zudaire
et al (2003)
Anti-AM blocking antibody Inhibition of AM activity Not tested Decreased mean
vessel area in tumour
xenografts
Ouafik et al (2002)
Positive nonpeptidic
regulators
Binding to AM Vasodilation in vivo Not tested Martinez et al
(2004a,b)
Negative nonpeptidic
regulators
Binding to AM Vasoconstriction Not tested Martinez et al
(2004a,b)
Receptor Fragmentary peptides
AM22-52 (receptor
antagonist)
CGRP8-37 (receptor
antagonist)
Competition with ligand
for binding to the receptor
Short half-life
Short half-life
Not tested
Not tested
Poyner et al (2002)
Poyner et al (2002)
Anti-CL blocking antibody
Anti-RAMPs blocking
antibodies
Direct interaction with
receptor has been
suggested
Not tested
Not tested
Inhibit HUVEC migration
and capillary tube
formation in vitro
Fernandez-Sauze
et al (2004)
Nonspecific modulators of AM-induced effects
Signalling cascades
(secondary messengers)
Wortmannin (PI3K
inhibitor) PD98059
(MAPK inhibitors)
Inhibition of ligand-induced
phospohorylation of
secondary messengers/
kinases
Nonspecific
Nonspecific
Prevent angiogenesis
in vitro and in vivo
Kim et al (2003)
Kim et al (2003)
Unknown Vinblastine Interaction with
cytoskeleton
Nonspecific Interruption of AM-induced
capillary-like tube formation
Ribatti et al (2003)
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their role in human cancer is as yet poorly defined. There exists
an urgent need for a greater assessment of AM as a novel tumour
marker. In the first place this requires a knowledge of the expression
at the mRNA and protein level of AM and CL in human normal and
tumour tissues. Ideally, this would involve correlation of expression
levels in patients with clinico-pathological data. Expression studies
have shown AM (like VEGF) to be widely expressed in normal adult
tissue. Expression is greatest in the placenta and endometrium that
are undergoing active angiogenesis, but was also significant in the
adrenal medulla, lung and kidney (Kitamura et al, 1993b). A more
detailed analysis nevertheless suggests that in some cases tumour
expression is greater than that in corresponding normal tissue,
for example, kidney where it is many fold higher (L. Nikitenko,
unpublished work). Several in vitro studies have demonstrated that
hypoxia upregulates AM expression in tumour cells and this needs
to be validated in vivo by, for example, in situ hybridisation (Rocchi
et al, 2001). The accurate determination of AM peptide in tissues is
far from straightforward. There is no readily available ELISA for AM
leaving radioimmunoassay as the most sensitive assay (Satoh et al,
1995; Oehler et al, 2003). Interpretation of the results is confounded
by the existence of adrenomedullin binding protein-1 (AMBP-1) and
the question of how much AM is bound to AMBP-1 or free
(reviewed in Zudaire et al, 2003).
Adrenomedullin as a therapeutic target
There is a need to identify the tumour types where expression of
AM and its receptors correlate with, for example, vascularisation,
prognosis and resistance to chemotherapy. This would single
out tumours in which AM plays a role and where anti-AM
therapeutic intervention may have potential. That antibodies
to AM reduce tumour growth in animal models was a significant
observation reminiscent of similar observations with anti-VEGF
antibodies a decade earlier. The VEGF studies eventually led
to the development of the anti-VEGF drug ‘Avastin’ and its efficacy
in the treatment of advanced metastatic colon cancer (Hurwitz
et al, 2004). Nevertheless, Avastin-treated tumours eventually
re-grow despite continued treatment, and it is potent angiogenic
factors such as AM that are likely to be responsible for the
breakthrough angiogenesis. One consideration is potential
side effects of AM-blocking antibody, since loss of AM results in
elevated blood pressure as demonstrated by studies in AM
knockout mice (Shindo et al, 2001). A detailed knowledge of
the interaction of AM with its receptors, and mechanisms
of their expression and function will provide insights that are
essential for the future development of chemical compounds and
antibodies that can modulate the activity of endogenous
AM receptors. Such drugs may have potential for antitumour
therapy.
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